Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bexicaserin in children and adults with Dravet syndrome
2024-514937-39-00Phase 3Authorised
- Sponsor
- Longboard Pharmaceuticals
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in Dravet syndrome comparing Bexicaserin with Placebo oral solution (2 arms). Primary endpoint: Frequency percent change in countable motor seizures during Maintenance compared to Baseline. Planned start May 2025; status: authorised.
02
Drugs
bexicaserin
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on 2024-514937-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514937-39-00.